Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (early spermatids) | 0.10 |
| chemistry Open Targets | compounds already reach it: ethoxzolamide, girentuximab, iodine i 124 girentuximab +1 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 1,425 | 0.85 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7984
Sealed predictions
- CA9 in dopamine neurons, braak-0.47 (p 0.197) → +0.00 (p 1.000)receipt 7992
Swarm cases
receipt 7992: CA9 in dopamine neurons, braak
- power
- full sample -0.19 (p 0.439, n 18), 95% CI -0.61 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.27 (p 0.285, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.58 (p 0.012, n 18). not the mix.
- skeptic
- leave-one-out range -0.30 to -0.09, sign flips 0; without severely affected donors -0.19 (p 0.439, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CA9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts